MARYLAND MEDICAID PHARMACY PROGRAM HIGH-COST DRUG STANDARD INVOICE PATIENT CLINICAL/Rx INFORMATION

Phone: 410-767-1455 or 1-800-492-5231 Option 3

Recipient:		_Age (On Medicare?	Yes	NoOthe	r insurance:
MA # :	(11 digit #)-	Current Boo	ly Weight:		_lbs or	kg
Address:			Tel.	#: ()	
Indication for prescribed Dru						
Required drug levels or bioc	hemical parameters- who	en applicable	to specific dr	ugs:		
Specify lab test:	J	Result:		Da	ite:/	/
Normal Range:						
High-Cost Drug:						
Dosage prescribed:						
	MANDATO	RY PRICIN	G INFORMA	TION		
Complete and sign the following n	nandatory section for the	high cost dru	ıg:			
Direct price charged by manufact	urer for high-cost drug.	\$	S	ne	er unit	
All discounts, chargebacks, rebat	es received:	\$		P	er unit.	
All discounts, chargebacks, rebat Actual acquisition cost paid for tl	ne high-cost drug:	\$		r	er unit.	
I attest that the above pricing info available for State audits.	ormation is accurate. Su	pporting doc	umentation as	to the pr	icing inforn	nation is
			()			
Purchasing Representative's orig Name of Purchasing Representati			Phone #			
		AIM INFOR				
ervice Provider # : Provider NPI #:	Tel # Tel # Pharmacy Nai Date \	() me: Written:	-)	
Provider NPI #:	Tel # Pharmacy NaiDate \ separate Rx# per drug N	() me: Written: DC.		/		
Provider NPI #:	Tel # {Pharmacy NarDate ' separate Rx# per drug N	() me: Written: DC.		/	Ouantity:	
Provider NPI #:	Tel # {Pharmacy NarDate ' separate Rx# per drug N	() me: Written: DC.		/	Ouantity:	
Provider NPI #:	Tel #Pharmacy Nar	me:	gth gth nat I will be me efore the actua ect to audits.	onitoring	Quantity: Quantity::_ the recipier are submitte	nt's therapy. All ed for payment.
Provider NPI #:	Tel #Pharmacy Nar	me:	gth	onitoring al claims	Quantity: Quantity::_ the recipier are submitte	nt's therapy. All ed for payment.
Provider NPI #:	Tel #Pharmacy Nar	me:	gth	onitoring	Quantity:Quantity::_ the recipier are submitte send to:	nt's therapy. All ed for payment.
Provider NPI #:	Tel #Pharmacy Nar	me:	gth	onitoring	Quantity:Quantity::_ the recipier are submitte send to:	nt's therapy. All ed for payment.
Provider NPI #:	Pharmacy Nate Ph	me:	gth	onitoring al claims	Quantity:Quantity::_ the recipier are submitte send to:	nt's therapy. All ed for payment.
Provider NPI #:	Pharmacy Nate Ph	me:	gth	onitoring al claims	Quantity:Quantity::_ the recipier are submitte send to:	nt's therapy. All ed for payment.
Provider NPI #:	Pharmacy Nate of Pharmacy Nate of Service dispensed are actor testing purpose must be are considered fraudule of Date of Systems, Operation of Cost Drug Dispensing on order.	me:	gth	onitoring all claims	Quantity: Quantity::_ the recipier are submitte - send to: Baltimore,	nt's therapy. All ed for payment. MD 21203:
Provider NPI #:	Pharmacy Name of Pharmacy Name of Service dispensed are actor testing purpose must be a reconsidered fraudule of Post Date of Systems, Operation of Cost Drug Dispensing on order.	me:	gth	onitoring al claims roice and ox 2158	Quantity:Quantity::_ the recipier are submitte send to:	nt's therapy. All ed for payment. MD 21203:

INSTRUCTIONS FOR COMPLETING THE HIGH-COST DRUG STANDARD INVOICE

Page 1 of 2

This form is mandatory for the specific drugs on the list of "Drugs Requiring Manual Review and Pricing" (See Table I). Providers may create a template of this form for computer-generated claims. Important points to note:

- The original signatures of the Dispensing Pharmacist and Purchasing Agent/Sales Manager are mandatory.
- Each Rx is valid for up to 365 days of therapy with a max of 11 refills per Rx, max 34-day supply per claim. Providers must bill one Rx # or one claim per drug NDC dispensed. For ex., a prescription for Cerezyme 1000U every 14 days may be filled with vials from 2 different strengths (200U and 400U) and should be billed as 2 separate claims. Billers must be aware of the proper unit of measurement in order to bill correctly. For ex., with Cerezyme, the unit for the powder vial is "each" for each vial. So, the quantity billed should be the # of vials and not the # of units. The units from 2 vials of different potencies cannot be combined and billed under one claim. The vials have different NDCs and are sent to the home in the unreconstituted form.
- High-cost drugs that are prepared by the home intravenous infusion pharmacist may not necessarily need manual pricing when they are not listed on Table I below. In this case, the paperwork does not need to be sent to the State. The pharmacist should call ACS for prior-auth for the "Cost Exceeds Max" exception code if the cost exceeds \$2,500. If 2 different package sizes (with 2 different NDCs) of the same product are dispensed, bill as separate claims for the 2 vials if dispensed as separate Rxs (i.e. Vivaglobin 6% in package sizes of 2ml and 20ml). The units of measurement for the unreconstituted vials are "ml' for the liquid (i.e. Vivaglobin, Adagen, etc.) and "each" for the powder (i.e. Cerezyme). For the active drugs, always bill the units of the unreconstituted vials. If the pharmacist should actually compound the drug by mixing the content of 2 different vial package sizes, then the 2 different vial NDCs should be billed as a compound, with compound code 2, under one claim, using the multi-line ingredient system functionality.
- The number of units billed must always reflect the dosage prescribed. A copy of the original Rx must accompany each invoice. A diagnosis should be documented on the invoice to rule out undocumented off-label use. Any changes affecting the drug used, dosage, and dosage frequency require a new signed Rx. Orders written "as directed" are not acceptable. Orders written "as needed" must have an approximate dosage frequency and/or a limit on the number of doses per day or per month. When required, a body weight must be documented to assist the pharmacist or the reviewer in determining proper dosage.
- Initiation of therapy for certain restricted high-cost drugs requires clinical prior-authorization to ensure appropriate prescribing of the medication besides service prior-authorization by the State to ensure proper billing by providers and proper drug utilization by the recipient. The Pre-Authorization for High-Cost Drugs Initiation of Therapy form must be completed by the prescriber and submitted to the Program for review of medical necessity. A copy of the patient's medical history must accompany the prior-authorization request. Depending on the therapy, continuation of therapy may require clinical reassessment of patient compliance, drug response, monitoring of drug levels and adverse effects.
- Certain drugs require close monitoring of specific drug levels or certain biochemical markers due to associated drug side-effects and high toxicity, as recommended or mandated by FDA. Such clinical information should be documented on the invoice and faxed routinely to the Program when the information is required to justify continuation of therapy and ensure patient safety while on the therapy.
- Any drug adverse effects, drug surplus due to missed doses, any wastage of expired medication, or any non-compliance issues must be documented on the Pharmacist High-Cost Drug Dispensing Record to justify the early or late refills.
- Automatic refills are not permitted as they may result in unnecessary drug accumulation and wastage. Providers should not set refills on "auto-mode" or program test claims to adjudicate on-line (if cost <\$2,500) even if they are capable of reversing the test claims when the actual claims are submitted. Some non-manual high cost drug claims (that do not require manual pricing) are for 2 different vial strengths, with one adjudicating because of the cost being<\$2,500.00 and the second vial with cost>\$2,500. Providers still need to call for prior-auth for the therapy involving both drug strengths, even though one drug strength had paid on-line. If the therapy quantity was billed or prescribed inappropriately, the entire therapy will be denied. Any claims that paid improperly will be subject to recovery by the Program. The recipient or caregiver must actually call the Pharmacy to request a refill. Early refills of a high-cost drug must be justified and documented on the Pharmacist High-Cost Drug Dispensing Record with valid reasons for the early refill request.

REQUIRING MANUAL REVIEW AND PRICING

Page 2 of 2

Bill as one claim per Rx# per drug NDC of the same product. If the product calls for use of various strengths necessitating multiple drug NDCs to be dispensed, bill multiple claims, one per drug NDC, per month as called for:

- 1. Enter Rx number and all required data elements. Use the actual single NDC for the high-cost drug. For an injectable drug, bill one claim (one Rx) per NDC if the vials are sent in the unreconstituted form to the recipient's home. May bill for the diluents used for reconstitution and dilution as separate claims if these are sent separately to the recipient's home. Submit claim with compound code 0 or 1 (non-compound).
- 2. If the drug should be compounded for the recipient (i.e. Aldurazyme), involving use of compounding supplies and diluents, bill only the active drug under the Pharmacy Program, as a single-line ingredient with compound code 1, using one Rx#. Bill the diluents and supplies under DME/DMS, using the proper HCPC codes. For recipients with no DME/DMS coverage benefits, bill the whole therapy as manual claims under the Pharmacy Program in order to get reimbursed for the supplies.
- 3. If there is a change in the dosage or dosage frequency, resulting in a different quantity being dispensed, a new prescription must be created and the claim submitted under a new Rx#.
- 4. The high-cost drug claim must be submitted on-line first for a denial. Claim will deny with NCPDP error code 75, "Prior-Authorization is required", error code M5 "Requires Manual Claim-Forward paper claim to the State", and error code 78 with the generic message, "Cost exceeds maximum- Contact ACS at 1-800-932-3918". There is no need to call ACS if the claim is a manual claim requiring manual review. Any DUR alerts and claim submission errors must be resolved. If a long-term clinical prior-authorization (PA) has been issued by the State, providers may go ahead and ship the drug in the correct amount and subsequently forward the paper work to the State for claim review, manual pricing and payment release. For drugs that require monitoring of lab data because of FDA-identified safety issues, providers should fax to the State the required documentation prior to shipping the drug to confirm approval of continuation of drug therapy based on the new lab results.
- 5. Complete the High-Cost Drug Standard Invoice and mail to **OSOP**, **PO Box 2158**, **Baltimore**, **MD 21203** along with all required documents, the Pharmacist High-Cost Drug Dispensing Record, a copy of the prescriber's order and proof of delivery DO NOT FAX BATCHES OF MANUAL CLAIMS TO THE STATE.
- 6. Claim will be returned if the required documents are missing. Keep all dispensing and prescription records on file for six years. Payments will be manually priced and released by the State.

Questions concerning completion of this form should be directed to the Maryland Pharmacy Program, Department of Health and Mental Hygiene at 410-767-5701.

TABLE I. DRUGS REQUIRING MANUAL REVIEW AND PRICING*

Adagen	
Aldurazyme, Elaprase, Naglazyme	Orfadin
Aralast, Prolastin, and Zemaira	
Ceredase and Cerezyme	
Fabrazyme	

This list is not inclusive. Newer high-cost drugs may be added to this list at a later date.

c:\ Word\ High-Cost Drug Standard Invoice & Billing Inst Sep 09